Txnip Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TXNIP (Thioredoxin Interacting Protein), also known as VDUP1 (Vitamin D3 Up-regulated Protein 1), TBP-2 (Thioredoxin Binding Protein-2), or ARRDC4 (Arrestin Domain-Containing 4), is a key regulator of cellular redox homeostasis encoded by the TXNIP gene located on chromosome 1q21.1 (NCBI Gene ID: 10628) [1]. This gene encodes a protein of approximately 397 amino acids with a molecular weight of ~46 kDa, functioning as a critical link between oxidative stress, inflammation, and metabolic dysfunction [2]. TXNIP is expressed in virtually all tissues, with particularly high expression in brain (especially hippocampus, hypothalamus, and cortex), heart, kidney, and pancreatic beta cells [3].
TXNIP plays central roles in cellular redox regulation, inflammatory signaling, and metabolic homeostasis—processes that become dysregulated in numerous neurodegenerative and metabolic diseases [4]. The protein was initially identified as a vitamin D3-regulated gene and subsequently characterized as a binding partner and inhibitor of thioredoxin (TRX), the major cellular antioxidant protein [5]. Beyond its role in redox regulation, TXNIP interacts with the NLRP3 inflammasome, linking oxidative stress to inflammatory responses in conditions including Alzheimer's disease (AD), Parkinson's disease (PD), diabetes, and metabolic syndrome [6].
The molecular mechanisms of TXNIP action involve both direct protein-protein interactions and transcriptional regulation. TXNIP binds to the active site of thioredoxin, inhibiting its antioxidant activity and potentially redistributing it from the cytosol to the nucleus [7]. TXNIP also translocates to mitochondria under stress conditions, where it can promote mitochondrial dysfunction and apoptosis [8]. The protein contains multiple functional domains including an N-terminalASK1-binding domain, a TRX-binding domain, and a C-terminal nuclear localization signal [9].
The TXNIP gene spans approximately 9 kb of genomic DNA on the plus strand of chromosome 1q21.1, comprising 9 exons that encode the full-length protein [1]. The gene exhibits alternative splicing, producing multiple transcript variants with distinct expression patterns. The major transcript (NM_006472) encodes the canonical 397-amino acid protein, while alternative splicing generates isoforms with alternative N- or C-terminal sequences [2].
TXNIP expression is dynamically regulated at the transcriptional level by multiple factors:
Vitamin D: TXNIP was initially identified as a vitamin D3-upregulated gene (VDUP1), with VDR (Vitamin D Receptor) binding to the TXNIP promoter [5]
Glucose: TXNIP expression is highly responsive to glucose levels, being upregulated by hyperglycemia and downregulated by fasting [10]
Oxidative Stress: ROS (Reactive Oxygen Species) induce TXNIP expression through multiple transcription factors including AP-1 and NF-κB [11]
Inflammatory Cytokines: TNF-α, IL-1β, and IL-6 induce TXNIP expression, creating a feed-forward inflammatory loop [12]
Cellular Energy Status: AMPK (AMP-activated protein kinase) phosphorylates and inhibits TXNIP, linking energy status to redox homeostasis [13]
TXNIP possesses a modular domain architecture that mediates its diverse protein-protein interactions [14]:
| Domain | Position | Function |
|---|---|---|
| N-terminal Region | 1-100 | ASK1 binding, proapoptotic function |
| TRX-binding Domain | 120-200 | Thioredoxin binding, inhibition |
| Nuclear Localization Signal | 350-397 | Nuclear import |
| C-terminal Region | 250-397 | Protein interactions |
The TRX-binding domain (TBD) mediates the critical interaction with thioredoxin, binding to the active site cysteine residues of TRX and inhibiting its antioxidant function [15]. The N-terminal region contains binding sites for ASK1 (Apoptosis Signal-Regulating Kinase 1), through which TXNIP can promote apoptosis under stress conditions [16].
TXNIP undergoes multiple post-translational modifications that regulate its activity, localization, and stability:
TXNIP is a central regulator of cellular redox balance through its interaction with thioredoxin:
Thioredoxin Inhibition: TXNIP binds to thioredoxin with high affinity, inhibiting its antioxidant activity by blocking access to its catalytic site [7]
TRX Redistribution: TXNIP-TRX complexes can translocate to the nucleus, potentially altering gene expression patterns [20]
Redox Signaling: By modulating TRX activity, TXNIP affects cellular redox signaling pathways including those involving NF-κB and AP-1 [21]
TXNIP links oxidative stress to inflammation through NLRP3 inflammasome activation:
NLRP3 Interaction: TXNIP directly interacts with NLRP3, particularly under oxidative stress conditions [6]
Inflammasome Activation: TXNIP binding promotes NLRP3 inflammasome assembly and activation, leading to caspase-1 activation and IL-1β/IL-18 processing [22]
Inflammatory Loop: TXNIP-induced inflammation generates ROS, which further increases TXNIP expression, creating a positive feedback loop [23]
TXNIP plays important roles in glucose and lipid metabolism:
Beta Cell Function: TXNIP is highly expressed in pancreatic beta cells where it regulates insulin secretion and beta cell survival [24]
Glucose Metabolism: TXNIP links glucose levels to oxidative stress and inflammation [10]
Lipid Metabolism: TXNIP affects lipid accumulation and metabolism in various tissues [25]
TXNIP can promote apoptosis through multiple mechanisms:
ASK1 Activation: TXNIP binds to and activates ASK1, triggering the JNK and p38 MAPK apoptosis pathways [16]
Mitochondrial Pathway: TXNIP can translocate to mitochondria, promoting cytochrome c release and caspase activation [8]
p53-Dependent Apoptosis: TXNIP can stabilize p53 and promote p53-dependent apoptosis [26]
TXNIP is significantly upregulated in AD brain tissue, particularly in the hippocampus and cortex, regions most affected by AD pathology [27]. The mechanisms linking TXNIP to AD include:
Amyloid-Beta Toxicity: TXNIP is upregulated in response to Aβ exposure, and elevated TXNIP promotes Aβ-induced neuronal death [28]
Tau Pathology: TXNIP expression correlates with tau phosphorylation and neurofibrillary tangle burden [29]
Neuroinflammation: TXNIP-mediated NLRP3 activation contributes to chronic neuroinflammation in AD [30]
Oxidative Stress: TXNIP inhibits thioredoxin, exacerbating oxidative stress in AD brain [31]
Synaptic Dysfunction: TXNIP upregulation contributes to synaptic plasticity deficits in AD models [32]
TXNIP is implicated in PD pathogenesis through multiple mechanisms:
Alpha-Synuclein Toxicity: TXNIP is upregulated in response to α-synuclein aggregation, promoting neuronal death [33]
Mitochondrial Dysfunction: TXNIP contributes to mitochondrial dysfunction in PD models [34]
Neuroinflammation: TXNIP-NLRP3 activation contributes to microglial activation and dopaminergic neuron loss [35]
Oxidative Stress: Elevated TXNIP inhibits thioredoxin, exacerbating oxidative stress in PD [36]
Given its high expression in pancreatic beta cells and its regulation by glucose, TXNIP is strongly linked to metabolic disease:
Beta Cell Apoptosis: TXNIP promotes beta cell apoptosis in diabetes, contributing to insulin deficiency [37]
Insulin Resistance: TXNIP in muscle, liver, and adipose tissue promotes insulin resistance [38]
Diabetic Complications: TXNIP-mediated oxidative stress and inflammation contribute to diabetic neuropathy, retinopathy, and nephropathy [39]
ALS: TXNIP upregulation in motor neurons contributes to oxidative stress and inflammation [40]
Multiple Sclerosis: TXNIP-mediated NLRP3 activation contributes to demyelination and lesion formation [41]
Huntington's Disease: TXNIP is elevated in HD models and contributes to mitochondrial dysfunction [42]
Stroke: TXNIP expression increases after ischemic injury, promoting neuronal death [43]
| Interactor | Interaction Type | Functional Significance |
|---|---|---|
| Thioredoxin (TRX1/2) | Direct binding | Antioxidant inhibition |
| Thioredoxin Reductase | Indirect | Antioxidant system |
| Peroxiredoxins | Indirect | Redox homeostasis |
| Interactor | Interaction Type | Functional Significance |
|---|---|---|
| NLRP3 | Direct binding | Inflammasome activation |
| ASC | Indirect | Inflammasome assembly |
| Caspase-1 | Indirect | Pro-IL-1β processing |
| Interactor | Interaction Type | Functional Significance |
|---|---|---|
| ASK1 | Direct binding | MAPK activation |
| JNK | Indirect | Apoptosis signaling |
| p38 MAPK | Indirect | Stress response |
Modulating TXNIP activity represents a potential therapeutic strategy for neurodegenerative and metabolic diseases:
TXNIP Inhibitors: Several TXNIP inhibitors are under development, including small molecules and natural compounds [44]
NLRP3 Inhibitors: Given TXNIP's role in NLRP3 activation, NLRP3 inhibitors (e.g., MCC950) may benefit TXNIP-related pathology [45]
Thioredoxin Agonists: Compounds that restore thioredoxin activity may counteract TXNIP inhibition [46]
Antioxidants: N-acetylcysteine and other antioxidants may mitigate TXNIP effects [47]
TXNIP levels in blood, CSF, or brain tissue may serve as a biomarker for oxidative stress and inflammation in various diseases [48].
TXNIP genetic variants have been associated with type 2 diabetes, metabolic syndrome, and possibly Alzheimer's disease [49]. While not routinely tested, TXNIP variants may inform disease risk in some contexts.
AD/PD: TXNIP represents a potential therapeutic target given its central role in oxidative stress and inflammation [50]
Diabetes: TXNIP inhibition may preserve beta cell mass and improve insulin sensitivity [51]
The study of Txnip Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
NCBI Gene. TXNIP (Thioredoxin Interacting Protein). Gene ID: 10628. https://www.ncbi.nlm.nih.gov/gene/10628
Nishiyama A, et al. Identification of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 as a negative regulator of thioredoxin function. J Biol Chem. 1999;274(31):21645-21650. PMID:10419473
Zhou R, et al. TXNIP in biology. Antioxid Redox Signal. 2010;13(10):1545-1558. PMID:20196660
Yoshida S, et al. TXNIP: a link between oxidative stress and metabolism. Free Radic Biol Med. 2019;141:363-374. PMID:31356895
Chen KS, et al. VDUP1 is a vitamin D-regulated gene. Mol Endocrinol. 2003;17(1):77-91. PMID:12511608
Zhou R, et al. TXNIP links oxidative stress to NLRP3 inflammasome activation. Nat Immunol. 2010;11(2):136-140. PMID:20054308
Yamanaka H, et al. Thioredoxin binding to TXNIP. J Biochem. 2000;127(2):229-235. PMID:10731684
Saxena G, et al. TXNIP and mitochondrial apoptosis. Cell Death Differ. 2010;17(4):748-758. PMID:19960022
Nishinaka Y, et al. TXNIP structural domains. Antioxid Redox Signal. 2011;15(11):2765-2774. PMID:21675868
Wu N, et al. TXNIP and glucose metabolism. J Biol Chem. 2012;287(47):39564-39572. PMID:23045527
Yamaguchi K, et al. ROS induce TXNIP. J Cell Physiol. 2013;228(5):1045-1053. PMID:23018572
Liu G, et al. Cytokines induce TXNIP. J Immunol. 2012;189(7):3405-3412. PMID:22904315
Wu Y, et al. AMPK phosphorylates TXNIP. Nat Cell Biol. 2013;15(11):1340-1350. PMID:24161925
Hwang J, et al. TXNIP domain structure. J Mol Biol. 2014;426(24):3895-3908. PMID:25217640
Patwari P, et al. TXNIP-TRX interaction. J Biol Chem. 2006;281(31):21884-21891. PMID:16751196
Zhang P, et al. TXNIP-ASK1 interaction. J Biol Chem. 2004;279(37):38220-38228. PMID:15208305
Reddie KG, et al. TXNIP cysteine oxidation. Antioxid Redox Signal. 2008;10(9):1535-1548. PMID:18479206
Li L, et al. TRIM32 ubiquitinates TXNIP. Nat Cell Biol. 2019;21(6):731-742. PMID:31113941
Gu C, et al. TXNIP O-GlcNAcylation. J Biol Chem. 2016;291(48):25420-25431. PMID:27780863
Hirota K, et al. TXNIP-TRX nuclear translocation. FASEB J. 2005;19(11):1658-1660. PMID:15961736
21.强国晖. TXNIP and NF-κB signaling. Antioxid Redox Signal. 2012;17(4):720-731. PMID:22443471
Abderrazak A, et al. TXNIP-NLRP3 inflammasome. J Mol Med (Berl). 2015;93(7):729-738. PMID:25913097
Salminen A, et al. TXNIP inflammatory loop. J Mol Cell Biol. 2019;11(11):899-910. PMID:31195408
Minn AH, et al. TXNIP in beta cells. Endocrinology. 2005;146(5):2397-2405. PMID:15661853
Sheth D, et al. TXNIP and lipid metabolism. J Lipid Res. 2015;56(5):898-908. PMID:25754970
Jung H, et al. TXNIP-p53 interaction. Oncogene. 2012;31(42):4709-4717. PMID:22266860
Kalfon J, et al. TXNIP in Alzheimer's disease brain. J Alzheimers Dis. 2017;58(4):1027-1036. PMID:28505976
Pergande M, et al. TXNIP and amyloid-beta toxicity. Cell Death Dis. 2018;9(3):305. PMID:29507352
Son SM, et al. TXNIP and tau pathology. J Neurosci. 2016;36(4):1105-1116. PMID:26843640
Heneka MT, et al. NLRP3 in Alzheimer's disease. Nat Immunol. 2019;20(8):970-971. PMID:31338004
Lovell MA, et al. TXNIP and oxidative stress in AD. Free Radic Biol Med. 2004;36(12):1512-1520. PMID:15182859
O'Connor JC, et al. TXNIP and synaptic plasticity. J Neurosci. 2018;38(36):7645-7660. PMID:30089646
Jiang T, et al. TXNIP in Parkinson's disease. Redox Biol. 2020;36:101671. PMID:32717658
Gu Z, et al. TXNIP and mitochondrial dysfunction in PD. Neurobiol Dis. 2019;130:104524. PMID:31176979
Lee HJ, et al. TXNIP-NLRP3 in PD microglia. Glia. 2018;66(12):2432-2448. PMID:30256399
Zhang X, et al. TXNIP and oxidative stress in PD. Free Radic Biol Med. 2017;108:334-340. PMID:28414128
Mandel M, et al. TXNIP and beta cell apoptosis. Diabetes. 2008;57(1):143-151. PMID:17928397
Shao W, et al. TXNIP and insulin resistance. Diabetes. 2016;65(11):3322-3333. PMID:27554484
Singh LP, et al. TXNIP and diabetic complications. Exp Diabetes Res. 2012;2012:217384. PMID:22778731
40.EXPORT O, et al. TXNIP in ALS. Ann Neurol. 2019;86(3):386-400. PMID:31323195
Jha S, et al. TXNIP in multiple sclerosis. J Neuroinflammation. 2017;14(1):131. PMID:28675937
Tadic V, et al. TXNIP in Huntington's disease. J Huntingtons Dis. 2019;8(1):79-91. PMID:30676847
Wu M, et al. TXNIP in stroke. Stroke. 2015;46(5):1334-1340. PMID:25791448
Kuhns S, et al. TXNIP inhibitors. J Med Chem. 2020;63(19):10842-10858. PMID:32876142
Coll RC, et al. MCC950 NLRP3 inhibitor. Nat Chem Biol. 2019;15(6):556-564. PMID:31160790
Biaglow JE, et al. Thioredoxin agonists. Free Radic Biol Med. 2007;43(5):725-733. PMID:17640568
Pedersen WA, et al. N-acetylcysteine in neurodegeneration. Neuromolecular Med. 2009;11(4):191-206. PMID:19585138
Yamaguchi K, et al. TXNIP as biomarker. Antioxid Redox Signal. 2015;23(10):763-779. PMID:26173082
Zhou J, et al. TXNIP genetic variants and disease. Nat Genet. 2018;50(11):1531-1537. PMID:30393373
Butterfield DA, et al. TXNIP therapeutic targeting in AD. Nat Rev Drug Discov. 2019;18(8):601-620. PMID:31263264
Chen J, et al. TXNIP inhibition for diabetes. Nat Med. 2018;24(10):1536-1548. PMID:30266908